Entresto is indicated for the treatment of:
b. Heart failure
d. Type II diabetes mellitus
e. Panic disorder
Answer: b. The active ingredients found in Entresto are Sacubitril and Valsartan. Sacubitril is a neprilysin inhibitor whereas Valsartan is an angiotensin II receptor blocker.
It is available as tablets (24/26 mg, 49/51 mg and 97/103 mg).
It is indicated:
1. to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
2. for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
Hypotension, hyperkalemia, cough, dizziness and renal failure are reported side effects of the drug.
Try our Naplex QBank. www.pharmacyexam.com